경동제약

011040KOSDAQ

55.5 / 100

Reference Date: 2026-10-23

Financial Score23.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongdong Pharmaceutical, established in 1976, is a company specializing in the manufacturing and sales of pharmaceuticals. Its business segments include pharmaceuticals (accounting for ~95% of sales), leasing, and others. Key products include DuoLoban tablets and Alpotin soft capsules, targeting rising demand due to aging populations and Western dietary habits. The company is expanding exports and developing new products, including OTC drugs and health supplements.

Number of Employees

363people

Average Salary

56.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

15.70Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR

0.67Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

3.76Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

10.24Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲151.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.8% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 4,960Won52-week high 6,16052-week low 4,720

1-month return3.0Point

1m -1% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-21
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08